USSN: 08/918,537

## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (currently amended) A composition of mammalian common lymphoid progenitor cells, wherein at least 95% of the cells in said composition are characterized as c-kit<sup>lo</sup>, IL-7R $\alpha$ <sup>+</sup>, lin<sup>-</sup>; and wherein an individual <u>c-kit<sup>lo</sup></u>, IL-7R $\alpha$ <sup>+</sup>, lin<sup>-</sup> progenitor cell in said composition is capable of giving rise to each of T cells, B cells, and natural killer cells, but not to myeloid cells.
- 2. (original) A composition of mammalian common lymphoid progenitor cells according to Claim 1, wherein said cells are blast cells.
- 3. (original) A composition of mammalian common lymphoid progenitor cells according to Claim 1, wherein said cells are further characterized as Thy-1<sup>-</sup>.
- 4. (original) A composition of mammalian common lymphoid progenitor cells according to Claim 1, wherein said cells are mouse cells, and are further characterized as Sca-1<sup>lo</sup>.
- 5. (currently amended) A composition of mammalian common lymphoid progenitor cells according to Claim 1, wherein said cells are further characterized as CD43<sup>lo</sup>, HSA<sup>lo</sup>, and CD45<sup>+</sup> and MEL-14<sup>-</sup>.
- 6. (original) A composition of mammalian common lymphoid progenitor cells according to Claim 1, wherein said cells are genetically modified to comprise an exogenous DNA vector.
- 7. (currently amended) A method of enrichment for a composition of mammalian common lymphoid progenitor cells, wherein at least 95% of the cells in said composition are characterized as c- $kit^{lo}$ , IL- $7R\alpha^+$ ,  $lin^-$ ; and wherein an individual  $\underline{c}$ - $kit^{lo}$ , IL- $7R\alpha^+$ ,  $lin^-$  progenitor cell in said composition is capable of giving rise to each of T cells, B cells, and natural killer cells, the method comprising:

combining reagents that specifically recognize c-kit,  $\frac{\|L-7R-\|}{\|L-7R-\|}$  and  $\frac{\|L-7R-\|}{\|L-$ 

selecting for those cells that are c-kit<sup> $^{\prime}$ </sup>, IL-7R $\alpha^{+}$ , lin $^{-}$ , to provide an enriched population of cells having lymphoid lineage progenitor activity.

USSN: 08/918,537

- 8. (original) A method according to Claim 7, wherein said sample of hematopoietic cells is bone marrow.
- 9. (original) A method according to Claim 7, wherein said sample of hematopoietic cells is mobilized peripheral blood.
- 10. (original) A method according to Claim 7, further comprising the step of selecting by size for blast cells.
- 11. (original) A method according to Claim 7, wherein said cells are mouse cells, and further comprising the steps of:

combining reagents that specifically recognize Sca-1 with said sample of hematopoietic cells; and

selecting for those cells that are Sca-1<sup>lo</sup>.

12-18 (canceled).

- 19. (currently amended) An isolated mammalian hematopoietic cell characterized as c-kit<sup>lo</sup>, IL-7R $\alpha$ <sup>+</sup>, lin<sup>-</sup>, wherein said cell is capable of differentiating into T cells, B cells, and natural killer cells, but not into myeloid cells.
- 20. (previously presented) The cell according to claim 19, further characterized as Thy-1<sup>-</sup>.
- 21. (currently amended) The cell according to claim 19, herein wherein said cell is a mouse cells, and is further characterized as Sca-1<sup>lo</sup>.
- 22. (currently amended) The cell according to claim 19, further characterized as CD43<sup>lo</sup>, HSA<sup>lo</sup>, and CD45<sup>+</sup> and MEL-14<sup>-</sup>.